Bavarian Nordic Announces Phase 2 Trial Investigating … – GlobeNewswire (press release)
|
Bavarian Nordic Announces Phase 2 Trial Investigating …
GlobeNewswire (press release) COPENHAGEN, Denmark, March 8, 2018 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb's nivolumab (OPDIVO®) in patients with metastatic … |
